Naloxone-precipitated jumping activity in mice following the acute administration of morphine

doi:10.1016/0014-2999(74)90084-3

European Journal of Pharmacology

Volume 26, Issue 1, April 1974, Pages 122-124

https://doi.org/10.1016/0014-2999(74)90084-3 Get rights and content

Abstract

Jumping behavior in mice was elicited by naloxone as early as 10 min after acute administration of morphine. The jumping response was determined to be time dependent and a function of both morphine and naloxone dosage. It is suggested that jumping behavior in mice may result either from a sensitization or unmasking action by morphine to a stimulatory effect of naloxone or from an unantagonized stimulatory action of morphine.

References (7)

C. Barthelemy et al.
Naloxone precipitated abstinence after one single injection of morphine and effects of naloxone on single dose tolerance to morphine
J. Pharmacol. (Paris)
(1972)
D.L. Cheney et al.
Tolerance to opioid narcotics: time course and reversibility of physical dependence in mice
Nature
(1971)
M. Kaneto et al.
Studies on physical dependence inducible by hours exposure of mice to morphine
Japan J. Pharmacol.
(1972)

There are more references available in the full text version of this article.

Cited by (80)

Divergent profiles of fentanyl withdrawal and associated pain in mice and rats
2021, Pharmacology Biochemistry and Behavior
Citation Excerpt :
While both humans and non-human animals are impacted by affective and emotional components of withdrawal (Liu et al., 2008; Bruijnzeel et al., 2006; Schulteis and Koob, 1996; Higgins and Sellers, 1994), here we chose to focus on somatic signs and hyperalgesia. A similar spectrum of withdrawal signs occurs in rat and mouse models of spontaneous and naloxone-precipitated morphine withdrawal (Gellert and Holtzman, 1978; Papaleo and Contarino, 2006; Towers et al., 2019; Schulteis et al., 1997; Kosersky et al., 1974; Way et al., 1969). However, few studies directly compare the withdrawal nuances in different rodent species within the same report.
Opioid abuse has devastating effects on patients, their families, and society. Withdrawal symptoms are severely unpleasant, prolonged, and frequently hinder recovery or lead to relapse. The sharp increase in abuse and overdoses arising from the illicit use of potent and rapidly-acting synthetic opioids, such as fentanyl, highlights the urgency of understanding the withdrawal mechanisms related to these drugs. Progress is impeded by inconsistent reports on opioid withdrawal in different preclinical models. Here, using rats and mice of both sexes, we quantified withdrawal behaviors during spontaneous and naloxone-precipitated withdrawal, following two weeks of intermittent fentanyl exposure. We found that both mice and rats lost weight during exposure and showed increased signs of distress during spontaneous and naloxone precipitated withdrawal. However, these species differed in their expression of withdrawal associated pain, a key contributor to relapse in humans. Spontaneous or ongoing pain was preferentially expressed in rats in both withdrawal conditions, while no change was observed in mice. In contrast, withdrawal associated thermal hyperalgesia was found only in mice. These data suggest that rats and mice diverge in how they experience withdrawal and which aspects of the human condition they most accurately model. These differences highlight each species' strengths as model systems and can inform experimental design in studies of opioid withdrawal.
Biphasic regulation of the acute μ-withdrawal and CCk-8 contracture responses by the ORL-1 system in guinea pig ileum
2012, Pharmacological Research
Citation Excerpt :
The withdrawal response of the tissue from the state of opioid physical dependence is revealed by the addition of naloxone (NL) or other selective antagonists. This response is observed few minutes after the exposure to the opioids [6,20–22], thus indicating that the cellular mechanisms underlying the acute dependence in the myenteric plexus are similar to those ones observed in experimental animals and man [23–25]. In GPI, the acute withdrawal response is under the inhibitory control of several neuronal systems.
The cloning of the opioid-receptor-like receptor (ORL-1) and the identification of the orphaninFQ/nociceptin (OFQ/N) as its endogenous agonist has revealed a new G-protein-coupled receptor signalling system. The structural and functional homology of ORL-1 to the opioid receptor systems has posed a number of challenges in the understanding the often competing physiological responses elicited by these G-protein-coupled receptors.
We had previously shown that in guinea pig ileum (GPI), the acute μ-withdrawal response is under the inhibitory control of several systems. Specifically, we found that the exposure to a μ-opioid receptor agonist activates indirectly the κ-opioid, the A₁-adenosine and the cannabinoid CB₁ systems, that in turn inhibit the withdrawal response. The indirect activation of these systems is prevented by the peptide cholecystokinin-8 (CCk-8).
In the present study, we have investigated whether the ORL-1 system is also involved in the regulation of the acute μ-withdrawal response.
Interestingly, we found that in GPI preparation, the ORL-1 system is not indirectly activated by the μ-opioid receptor stimulation, but instead the system is able by itself to directly regulate the acute μ-withdrawal response.
Moreover, we have demonstrated that the ORL-1 system behaves both as anti-opioid or opioid-like system based on the level of activation. The same behaviour has also been observed in presence of CCk-8. Furthermore, in GPI, the existence of an endogenous tone of the ORL-1 system has been demonstrated. We concluded that the ORL-1 system acts as a neuromodulatory system, whose action is strictly related to the modulation of excitatory neurotrasmitters released in GPI enteric nervous system.
Involvement of the cannabinoid CB<inf>1</inf> receptor in the opioid inhibition of the response to cholecystokinin and acute withdrawal response
2005, NeuroToxicology
Numerous recent studies have reported major functional interactions between cannabinoid and opioid systems. These interactions can be studied in the myenteric plexus-longitudinal muscle isolated preparations. We had previously shown that in the guinea-pig ileum (GPI), the opioid acute withdrawal response is under the inhibitory control of several systems; μ-opioid agonist exposure indirectly activates the κ-opioid system; conversely, exposure to a κ-opioid agonist indirectly activates the μ-system; the indirectly activated opioid system inhibits the withdrawal response. The adenosine A₁ system is also indirectly activated by opioids and it inhibits the withdrawal response. We had also shown that indirect activation is prevented or antagonized by cholecystokinin (CCK-8).
In GPI preparations briefly exposed to the μ-agonist, dermorphine (DERM) and then challenged with naloxone (NL), the cannabinoid CB₁ antagonist, SR141716 (SR), increased the withdrawal responses to NL, but only did so in presence of a κ-opioid and an adenosine A₁ antagonist. Under similar experimental conditions, SR also enhances the κ-opioid withdrawal response. In opioid agonist/CCK-8/NL tests, SR antagonized the inhibition of the tissue response to CCK-8 induced by the μ- or κ-opioid agonist and increased the κ-withdrawal response, but not the μ-withdrawal response. However, the dose–response curve against dermorphine inhibition of the response to CCK-8 was bell-shaped and the highest SR concentration also significantly decreased the μ-withdrawal response. In preparations exposed to dermorphine or to the κ-agonist, U-50,488H, the cannabinoid agonist WIN 55,212-2 increased the opioid-induced inhibition of the tissue response to CCK-8 and decreased the NL-induced responses.
These results show that opioid exposure may also activate the cannabinoid CB₁ system, which leads to an inhibition of the opioid acute withdrawal response. This phenomenon and the antagonistic effect of SR on the opioid-induced inhibition of the response to CCK-8 suggest that reciprocal interaction between opioid and cannabinoid systems are operating in the enteric nervous system.
Naltrexone-induced conditioned place aversion following a single dose of morphine in the rat
2005, Pharmacology Biochemistry and Behavior
Limited preclinical research has been conducted investigating the motivational or “affective” properties of withdrawal from acute opioid dependence following a single morphine exposure. Therefore, the purpose of the present study was to pharmacologically characterize the motivational properties associated with naltrexone-precipitated withdrawal after a single injection of morphine using place conditioning. Conditioned place aversion was assessed using a biased two-compartment apparatus and procedure. Adult male Sprague–Dawley rats were given 15 min free access to the entire apparatus on day one to determine initial preferences. Beginning on the second day, combinations of either saline or morphine (1.0–10 mg/kg, s.c.) followed by naltrexone (0.003–3.0 mg/kg, s.c.) 3.75 h later were administered. Rats were then immediately confined to one compartment for 30 min. The next day, rats received the alternative treatment and were confined to the opposite compartment. Twenty-four hours later animals were tested again for 15 min while they had access to the entire apparatus. Morphine followed by naltrexone conditioned significant place aversion (CPA) with just one pairing. This effect was a function of the naltrexone and morphine doses. CPA was also dependent on morphine pretreatment time, with significant aversion only occurring 4 h after morphine pretreatment. Finally continuous morphine administration followed by a single injection of naltrexone resulted in CPA. These data extend the range of behavioral effects associated with antagonist-precipitated withdrawal from acutely administered morphine and suggest that place conditioning is an effective model in assessing motivational aspects of withdrawal from acute opioid dependence in rats.
Precipitated opioid withdrawal across acute physical dependence induction methods
2004, Pharmacology Biochemistry and Behavior
The phenomenon of acute opioid physical dependence (APD) is an established and well-characterized experimental model for studying the clinical phenomenon of physical dependence to opioids in humans. In this paradigm, an opioid withdrawal syndrome is elicited in non-opioid-dependent humans by the parenteral administration of naloxone (NX) following a single large dose of opioid agonist. Although induced by various opioids and NX administration schedules, lacking is a direct comparison of different induction protocols with respect to withdrawal severity. Using a crossover design, we compared withdrawal severity in four healthy male subjects pretreated with morphine (MS; 18 mg/70 kg im), MS (10 mg/70 kg iv) and hydromorphone (HM; 2 mg/70 kg) followed 2 or 6 h later with NX (10 mg/70 kg iv). Dependent measures included both physiological and subjective indicators of withdrawal. All opioid pretreatments reliably induced APD and repeated-measures analysis of variance (ANOVA) showed that both pattern and severity of precipitated withdrawal were similar across conditions. Thus, despite altering the pretreatment opioid and route of administration, all three APD protocols produced similar and reliable withdrawal symptoms in humans.
Purinoreceptors are involved in the control of acute morphine withdrawal
2001, Life Sciences
The effects exerted by P1 and P2 purinoceptor agonists and antagonists on the acute opiate withdrawal induced by morphine were investigated in vitro. Following a 4 min in vitro exposure to morphine, the guinea-pig isolated ileum exhibited a strong contracture after the addition of naloxone. The P1 purinoceptor agonist, adenosine, was able dose-dependently to reduce morphine withdrawal whereas α,β-methylene ATP (APCPP), a P2 purinoceptor agonist, increased morphine withdrawal. Caffeine, a P1 purinoceptor antagonist, was able significantly and in a concentration dependent manner to increase morphine withdrawal whereas quinidine, a P2 receptor antagonist, reduced it. The results of our experiments indicate that both P1 and P2 purinoceptor agonists and antagonists are able to influence opiate withdrawal in vitro, suggesting an important functional interaction between the purinergic system and opioid withdrawal.

View all citing articles on Scopus

¹: Present address: Department of Medicinal Chemistry and Pharmacology, College of Pharmacy and Allied Health Professions, Northeastern University, Boston, Massachusetts 02115, U.S.A.

²: Present address: Department of Pharmacology, School of Medicine, University of California, San Francisco, California 94143, U.S.A.

³: Present address: Department of Pharmacology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23219, U.S.A.

View full text

Short communicationNaloxone-precipitated jumping activity in mice following the acute administration of morphine

Abstract

Naloxone precipitated abstinence after one single injection of morphine and effects of naloxone on single dose tolerance to morphine

J. Pharmacol. (Paris)

Tolerance to opioid narcotics: time course and reversibility of physical dependence in mice

Nature

Studies on physical dependence inducible by hours exposure of mice to morphine

Japan J. Pharmacol.

Short communication
Naloxone-precipitated jumping activity in mice following the acute administration of morphine